RecruitingPhase 2

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

Canada60 participantsStarted 2024-05-20

Plain-language summary

There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia. No randomized controlled trial has been performed. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Adult \>=18 years old
✕. S. aureus bacteremia within the past 48 hours:
✕. Current receipt of cefazolin or where it would be clinically appropriate (according to treating ID specialist) to switch to cefazolin as the backbone therapy (open label, non-study drug).
✕. At time of recruitment, the patient has already clinically improved with at least one subsequent negative culture at \>24 hours incubation
✕. Anaphylaxis to any beta-lactam antibiotic (and any allergy to ertapenem) Polymicrobial bacteremia (not including skin commensals)
✕. Known seizure disorder
✕. Any receipt of valproic acid
✕. Expected mortality within 48 hours

What they're measuring

Clinical success

Timeframe: Day 5

Trial details

NCT IDNCT04886284

SponsorTodd C. Lee MD MPH FIDSA

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04

Contact for this trial

Lina Petrella

514-934-1934 lina.petrella@muhc.mcgill.ca

View on ClinicalTrials.gov More Staphylococcus Aureus Bacteremia trials